» Articles » PMID: 39852123

Mechanisms and Emerging Regulators of Neuroinflammation: Exploring New Therapeutic Strategies for Neurological Disorders

Overview
Publisher MDPI
Date 2025 Jan 24
PMID 39852123
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroinflammation is a complex and dynamic response of the central nervous system (CNS) to injury, infection, and disease. While acute neuroinflammation plays a protective role by facilitating pathogen clearance and tissue repair, chronic and dysregulated inflammation contributes significantly to the progression of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis. This review explores the cellular and molecular mechanisms underlying neuroinflammation, focusing on the roles of microglia, astrocytes, and peripheral immune cells. Key signaling pathways, including NF-κB, JAK-STAT, and the NLRP3 inflammasome, are discussed alongside emerging regulators such as non-coding RNAs, epigenetic modifications, and the gut-brain axis. The therapeutic landscape is evolving, with traditional anti-inflammatory drugs like NSAIDs and corticosteroids offering limited efficacy in chronic conditions. Immunomodulators, gene and RNA-based therapeutics, and stem cell methods have all shown promise for more specific and effective interventions. Additionally, the modulation of metabolic states and gut microbiota has emerged as a novel strategy to regulate neuroinflammation. Despite significant progress, challenges remain in translating these findings into clinically viable therapies. Future studies should concentrate on integrated, interdisciplinary methods to reduce chronic neuroinflammation and slowing the progression of neurodegenerative disorders, providing opportunities for revolutionary advances in CNS therapies.

Citing Articles

LRRK2 in Drosophila Melanogaster Model: Insights into Cellular Dysfunction and Neuroinflammation in Parkinson's Disease.

Ciampelli C, Galleri G, Galioto M, Mereu P, Pirastru M, Bernardoni R Int J Mol Sci. 2025; 26(5).

PMID: 40076730 PMC: 11900240. DOI: 10.3390/ijms26052093.

References
1.
Caldito N . Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders. Front Immunol. 2023; 14:1213448. PMC: 10360935. DOI: 10.3389/fimmu.2023.1213448. View

2.
Fan X, Zhang Y, Li X, Fu Q . Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 2020; 77(14):2771-2794. PMC: 7223321. DOI: 10.1007/s00018-020-03454-6. View

3.
Bennett C, Krainer A, Cleveland D . Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annu Rev Neurosci. 2019; 42:385-406. PMC: 7427431. DOI: 10.1146/annurev-neuro-070918-050501. View

4.
Adamu A, Li S, Gao F, Xue G . The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Front Aging Neurosci. 2024; 16:1347987. PMC: 11045904. DOI: 10.3389/fnagi.2024.1347987. View

5.
Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M . NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024; 9(1):53. PMC: 10910037. DOI: 10.1038/s41392-024-01757-9. View